Business Wire

TX-PLANVIEW

Share
Planview Releases Global Benchmark Report that Reveals How Leading Companies Accelerate On-Strategy Delivery in Times of Change

Planview, a global leader in Portfolio Management and Work Management solutions, today published a global report that unlocks how companies are successfully responding to continuous market disruption, accelerating innovation and executing on their business strategies. Based on a first-of-its-kind study, the report, titled “The State of Strategy Execution: Embracing Uncertainty to Adapt at Speed ,” uncovers why many companies are challenged to pivot strategy in times of change, and provides pragmatic recommendations for companies to adapt more quickly to shifting conditions and disruptive events, and deliver quality business outcomes.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005214/en/

“This study was designed to answer a deceptively simple question: Why can some companies quickly adapt and even accelerate strategy execution during times of significant change, and others just get by?,” said Patrick Tickle, Chief Product Officer at Planview. “That question is of utmost importance not only today while we navigate the pandemic but for the foreseeable future. Market disruptions are no longer the exception. Disruption is the norm, and the smartest companies have learned how to not just survive but thrive in environments of constant change.”

Segmenting respondents into categories of Leaders, Challengers and Laggards, a clear picture emerged of what successful companies are doing and that others can replicate, including:

  • Prioritizing speed when it comes to making decisions and executing faster
  • Implementing technology that delivers faster business insights from data
  • Adjusting strategies, funding, and operating plans with short-interval planning cycles
  • Improving the prioritization process to realign resources to the most important work
  • Utilizing Lean and Agile business practices throughout the organization

This vital report goes beyond just analyzing why some organizations are more successful than others in quickly adapting to market disruptions. It provides a roadmap for how other companies can achieve success, streamline business processes to prioritize speed and quality, accelerate innovation, and improve strategic outcomes.

“Reducing the gap between strategy and execution becomes even more important as the pace of external disruption increases, and this report provides a clear blueprint about how leading companies are doing exactly that,” said Tickle. “We found that the most successful companies are following a similar recipe for success. They are building speed into their business operations to adjust to constant change. They have shorter, more adaptable planning cycles that enable them to respond to shifts in real-time. They remove internal barriers that stand in the way of adaptability. They resist the lure of the status quo. And they use technology and agile processes to build speed and quality into the way they execute on strategy.”

Based on a global benchmarking analysis of nearly 1,000 business and technology professionals at organizations across a wide range of industries around the world, the survey was commissioned by Planview and conducted by independent research firm Lawless Research. Results uncovered why many companies struggle to quickly respond to change and disruption:

  • Complex governance or approval processes (38%)
  • Unclear or conflicting priorities (33%)
  • Lack of resources to complete all approved projects (31%)
  • Lack of organizational alignment (departmental silos) (31%)

To read the full report and its detailed set of recommendations, visit: The State of Strategy Execution: Embracing Uncertainty to Adapt at Speed . To get more insights into the best practices utilized by many of the successful companies in the benchmarking study, visit: Managing Transformation: Connect Strategy to Delivery to Dynamic Business Today .

Survey Methodology

Planview commissioned a survey, undertaken by an independent research organization, Lawless Research, in December 2020. Nearly 1,000 business and technology professionals across multiple countries were surveyed, including: Australia, France, Germany, United States, and the UK. Companies were from a range of industries, including banking and financial, technology, retail, manufacturing, healthcare, business services, government and public sector, travel and hospitality, engineering, and more. The corresponding report provides pragmatic recommendations for business, technology, and finance leaders seeking to create a tight connection between strategy and execution, adapt more quickly to shifting conditions and disruptive events, and deliver quality business outcomes.

About Planview

Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions enable organizations to navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 1,000 employees supporting 4,500 customers and 1.3 million users worldwide. For more information, visit: www.planview.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye